Living Cell Technologies Limited (LCT)

Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today » it's FREE! Already a member? Login now!

General Information
Company Name: Living Cell Technologies Limited
Stock Code: LCT
GICS Sub-Industry: Biotechnology
Market Cap ($M): 32
Equiv. Shares (M): 406

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
$ 0.078 $ 0.077 $ 0.078 $ 0.074 $ 0.078 330,103 0%

Company Overview

Business Description:
Living Cell Technologies (LCT) develops cell therapies to treat diseases with high unmet clinical needs. The Australasian biotechnology company is a global pioneer in the field of cell encapsulation and implantation for human therapeutics. To date, the company has taken two therapeutic candidates into clinical development: DIABECELL® for the treatment of type 1 diabetes and NTCELL®, which is in Phase I clinical trials in New Zealand for the treatment of Parkinson’s disease.

Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2014  A -6.8 -1.9 -- 0.0 0.0 0.0 --
2013  A -3.0 -0.8 -- 0.0 0.0 0.0 --
2012  A 5.7 1.7 -- 3.7 0.0 0.0 --
Source: Aspect actuals / Thomson IBES estimates

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F
Bionomics (BNO) $205 M -- 6.3117 0.3108 63.6364 8.7034 6.6396 0.00 0.00 0.00
CSL (CSL) $37,337 M 0.0899 0.2412 0.0806 27.5143 22.1683 20.5147 1.53 1.83 2.04
Living Cell (LCT) $31 M -- -- -- -- -- -- 0.00 -- --
Mesoblast (MSB) $1,280 M -- -- -- -- -- -- 0.00 0.00 0.00
Sirtex Medical (SRX) $1,475 M 0.2906 0.5155 0.3526 63.1961 41.7000 30.8292 0.54 0.66 1.06

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
LCT -- -- 3.31 -- 3.77
Market 1.14 13.5 0.99 1.03 3.03
Sector 0.81 18.0 2.78 1.24 7.45

Name Position Start Date
Professor Robert Bartlett Elliott Medical Director 15 January 2004
Mr Robert Moyse Willcocks Non-Executive Director 29 March 2011
Mr Laurrie Hunter Non-Executive Director 25 August 2006
Dr Bernard Tuch Non-Executive Director 19 July 2011
Mr Roy James Austin Non-Executive Director,Non-Executive Chairman 25 February 2011

Name Position
Kenneth (Ken) P Taylor Chief Executive Officer
Nicholas (Nick) John Victor Geddes Company Secretary
John Cowan Head of Finance & Administration

Substantial Shareholders
Holding Name
12,329,061 (3.45%) K One W One Limited
25,610,891 (7.17%) Persistency Private Equity Limited (formerly Prospector Limited)
24,150,408 (6.76%) Palmert Members Limited
24,150,408 (6.76%) Coalco International Limited
25,000,000 (7.00%) Otsuka Pharmaceutical Factory, Inc

Calendar of Events
Date Event
16 October 2015 Report (Annual)
14 August 2015 Report (Prelim)
24 February 2015 Report (Interim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at


Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Debt Relief

An educational booklet to help you take control of your debts and look to get back on track.

More details...


Australian Share Market - Close Up

CMC Markets 11/11/2014 | The Australian share market is in a decision zone - and trading from here may set the direction for the rest of the year.

Prices slashed - everything must go!

Nick Swales, Regional Director, Newcastle Office, Rathbones 27/10/2014 | “If you want to have a better performance than the crowd, you must do things differently from the crowd.” Sir John Templeton.

Aussie share market bulls now have company

Ric Spooner (Chief Market Analyst, CMC Markets) 20/10/2014 | Today, Australian investors will not have to go it alone buying stocks as they did for much of last week. Bargain hunters this morning will be supported by the morale boosting encouragement of a 3% turnaround in the German Dax and a 264 point rally in the Dow Jones.

The Importance of Ignoring the Noise of the Market

Carl Richards, director of investor education at the BAM Alliance 17/10/2014 | “As odd as it may sound, the sooner you start treating your investments like you treat life, the happier you’ll be with the outcome.”

You only dance twice

William H. Gross, Janus Capital Group 16/10/2014 | “Financial markets are artificially priced. In the bond market, there is nothing normal about a three year German Bund yielding “minus” 10 basis points.”

The Big Picture - Australia 200 Index

CMC Markets 8/10/2014 | Share market indices around the globe are breaking down. While analysts cast around for reasons, it’s clear that a time factor is in play. Simply put, many investors “feel” a correction is overdue. How low could it go?


Sponsored Links